Nanosponges: Novel Drug Delivery for Treatment of cancer
The problems faced due to the conventional drug delivery system have been defeated after the invention of nanosponges (NS). NSs drug delivery system is considered as the novel drug delivery system which has emerged as one of the most successful fields in life sciences. Nanosponges have been proved to be a boon in the treatment of cancer. Conventional drug delivery system, used in the treatment of cancer is generally insoluble and produces serious side effects. Thus, nanosponges are used in which the active drug is entrapped in a complex of polymers such as cyclodextrins. The drug is released from these nanoparticles to the specific targeted tumor sites and produce optimum therapeutic effect and minimal side effects. The nanosponges are generally biodegradable in nature. The solubility of the drug is increased due to which hydrophobic drugs can be incorporated within the NSs. The patient compliance is also improved due to this type of drug delivery system. Various factors which influence the drug delivery of NSs are the type of polymer used, type of drug incorporated, temperature, method of preparation and degree of substitution. The NSs are formulated by maintaining the above factors. The methods used are solvent method, melt technique, ultra-sound assisted synthesis, emulsion solvent diffusion method and loading the drug into the NSs. NSs are either crystalline or paracrystalline which have different loading capacities. This review mainly focuses on the nanosponges used as anticancer agents. The factors, method of formulation of the nanosponges are discussed in detail.
Keywords: Nanosponge, biodegradable, polymers, minimal side effects, targeted tumor sites.
2. Osmani RA, Aloorkar NH, Kulkarni PK, Hani U, Thirumleswar S et al. Novel cream containing microsponges of anti-acne agent: Formulation development and evaluation. Curr drug delivery 2015; 12:504-16.
3. Pushpalatha R, Selvamuthukumar S, Kilimozhi D. Nanocarrier mediated combination drug delivery for chemotherapy- A review. J drug delivery science technology 2017; 39:362-71.
4. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr cancer Drug Targets 2002; 2:209-26.
5. Nie S, Xing Y, Kim GJ, Simons JW. Nanotehnology applications in cancer. Annu Rev Biomed Eng 2007; 9:257-88.
6. Fojo T, Baates S. Strategies for reversing drug resistance. Oncogene 2003; 22:7512-23.
7. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Science 2003; 94:15:15-21.
8. Bolmal UB Manvi FV, Rajkumar K, Palla SS, Paladugu A, Reddy KR. Reent advances in nanosponges as drug delivery system. Int J Pharm Sci Nanotechnology 2013; 6:1934-44.
9. Himangshu Bhowmik, D. Nagaswamy Venkatesh, Annutam Kuila, Kammari Harish Kumar. Nanosponges : A review. International journal of applied pharmaceutics. 2018; 10:0975-7058.
10. Lee CL, Wu CC, Chiou H, Syu , Huang C, Yang C. Mesoporous platinum nanosponges as electro catalysis for the oxygen reduction reatiion i an acidic electrolyte. Int J hydrogen energy 2011; 36:6433-40.
11. Swaminathan S, Cavalli R, Trotta F. Cylodextrin- based nanosponges: A versatile platform for cancer nanotherpeutics development. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016; 8:579-601.
12. Nikita S, Vishal GN, Sandeep K. A review on nanosponges: a boon to targeted drug delivery for anti caner drug. Asian J of pharmaceutical and clinical research 2019; 12:7.
13. Amber V, Shailendra S, Swarnalatha S, J incl phenomena macrocycl chem., 2008,62,23-42.
14. Rajeswari, Alka A, Javed A, Khar RK, AAPS Pharm sci Tech, 2005,6, E329-E357.
15. Jyoti P, Tulsi B, Popin K, Chetna B. An Innovative advancement for targeted drug delivery: Nanosponges. Indo global J of Pharm Sci. 2016; 6(2):59-64.
16. Sharma R, Pathak K. Nanosponges: Emerging drug delivery system. Pharm Stud; 2010.p.33-5.
17. Yadav G, Panchory H. Nanosponges: A boon to the targeted drug delivery system. J of Drug Delivery and therapeutics; 2013, 3(4):151-155.
18. Dou M, Huang G, Xi Y, Zhang N. Orthogonal experiments for optimizing the formulation and preparation conditions of temozolomide solid lipid nanoparticle. Sheng Wu YI Xue Gong Cheng Xue Za Zhi. 200825:1141-5.
19. Jain D, Gursalkar T, Bajaj. Nanosponges of an anticancer agent for potential treatment of brain tumors Am J Neuroprot Neurogen 203; 5:332-43.
20. Ma P, Mumper RJ. Paclitaxel Nano- Deelivery systems: A comprehensive review. J Nanomed Nano technology; 203; 4(2):1000164.
21. Kurien BT, Singh A, Matsumoo H, Scofielf RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment Assay drug Dev technol 2007; 5:567-76
22. Naksuriya O, Okonogi S, Shiffelers RM, Hennik WE. Curcumin nanoformulations: A review of pharmaceutical properties and pre clinical studies and clinical data related to cancer treatment biomaterials 2014; 35:3365-83.
23. Momin MM, Zaheer Z, Zainuddin R, Sangshetti JN. Extended release delivery of erlotnib glutathione nanosponge for targeting lung cancer. Artif cells nanomed biotechnol; 2018; 46(5):1064-1075.
24. Cavalli R , Akhter Ak, Bisazza A, Giustetto P, Trotta F, Vavia P. Naosponge formulation as oxygen delivery systems. Int J pharm; 2010; 402(1-2):254-7.
25. Trotta F, Cavalli R, Martina M, Biasizzo M. cyclodextrin nanosponges as effective gas carriers; J of incl phenomena; 71(1):189-194.
26. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J cancer Educ 2013; 4:644-52.
27. Bhaskar C, Ahmed F, Kondapi AK, Golla K. A target- specific oral formulation of doxorubicin protein nanoparticles: Efficacy and safety in hepatocellular cancer. J cancer educ 2013; 4:644-52.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).